Clinical Trial

Intermediate-size Patient Population Expanded Access Protocol

Available
View on ClinicalTrials.gov →
Summary
The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-07-18; most recent amendment 2026-07-16.
Trial Details
NCT Number NCT07088159
Lead Sponsor Spinogenix
Conditions ALS (Amyotrophic Lateral Sclerosis)
Updated on ClinicalTrials.gov 2026-07-17